Cutting Edge Cancer Treatments

James P. Stevenson, MD
Last Modified: November 1, 2001

Dear OncoLink "Ask the Experts,"
I am currently being treated with oxaliplatin for metastatic colon cancer in the liver. Where do you think the most promising future colon cancer help will come from angiogenesis inhibitors, monoclonal antibodies, or vaccines?  

James P. Stevenson, MD, Assistant Professor of Medicine in the Hematology/Oncology Division of the University of Pennsylvania School of Medicine, responds:

All of those agents (angiogenesis inhibitors, monoclonal antibodies, and vaccines) hold promise for colorectal cancer. At this point, no one agent seems to stand out. Examples of each that are being studied in colon cancer include;

  • SU5416 (an antiangiogenesis drug),
  • C225 (a monoclonal antibody),
  • multiple vaccines directed at CEA
It is likely that any of these will be more effective when combined with chemotherapy, and some drugs actually span both classes (for example, bevacizumab or anti-VEGF, which is a monoclonal antibody designed to be antiangiogenic). Results from trials of these agents in colon cancer are expected soon. Please speak to you oncologist about the possibility of participating in any clinical trial.